- Blood Glucose Meter
- Blood Glucose Testing Strips
- Lancets
- Others
Self-Monitoring Blood Glucose Devices Market size was valued at USD 12.82 billion in 2021. It is expected to reach a value of USD 22.84 billion by 2028, at a CAGR of 8.6% from 2022-2028. Self-monitoring blood glucose technology methods are small, portable devices that can detect disease risk. These instruments often take a tiny blood sample from patients by pricking their fingertips in order to measure their blood sugar levels. This approach is advised by international recommendations for effectively managing diabetes in patients. The blood glucose concentration is measured using a self-monitoring blood glucose monitor. The COVID-19 pandemic had a favourable effect on the expansion of the self-monitoring blood glucose market. Diabetes problems, aberrant glucose variability, and increased blood glucose levels may be experienced by COVID-19-infected patients who have diabetes. The COVID-19 emergency has highlighted the significance of self-monitoring blood glucose devices, therefore it is important to keep an eye on a patient's blood glucose monitoring to prevent aggravation. Going forward, it is anticipated that the market for self-monitoring blood glucose devices would expand due to the increased prevalence of diabetes. Self-monitoring of blood glucose is a technique whereby a person with diabetes uses a glycemic reading device to measure their blood sugar (glucose metre) so that they can adjust or monitor the effectiveness of their treatment (diet, exercise, insulin, antidiabetics), or see their doctor, based on the test results.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
A substantial proportion of persons in the United States carry genes for bleeding and clotting diseases, as well as hemoglobinopathies, according to the Office of Disease Prevention and Health Promotion. Blood clots in leg veins affect over 1.2 million people in the United States. Deep venous thrombosis is the medical term for this illness (DVT). Hemoglobin disorders were once endemic in 60 percent of 229 countries, potentially affecting 75 percent of births; however, they are now common in 71 percent of countries, affecting 89 percent of births (either in the entire population or among minorities), prompting policymakers to consider the most appropriate treatment and prevention strategy. A major variation affects at least 5.2 percent of the world's population (and over 7% of pregnant women). Due to a localised very high carrier prevalence, haemoglobin S accounts for 40% of carriers but causes over 80% of problems: over 85% of sickle-cell disorders and over 70% of all affected infants occur in Africa. As a result, the market is likely to be driven by increased blood diseases.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.